Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02763-2
Abstract: Although the combination of fludarabine and high-dose melphalan (FLU/MEL) has been widely used in allogeneic stem cell transplantation, high-dose MEL causes life-threatening adverse events, especially in elderly patients. To reduce the toxicity of MEL without… read more here.
Keywords: curative potential; elderly patients; non myeloablative; mel ... See more keywords
Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: clinical features, risk factors, and posaconazole profiles.
Sign Up to like & getrecommendations! Published in 2023 at "Medical mycology"
DOI: 10.1093/mmy/myad046
Abstract: Posaconazole (PSC) delayed-release tablet prophylaxis is the standard of care for preventing invasive fungal infection (IFI) in patients with acute myeloid leukemia undergoing myelosuppressive chemotherapy. The clinical features, risk factors, and PSC profiles of breakthrough… read more here.
Keywords: tablet prophylaxis; risk factors; myeloid malignancy; patients myeloid ... See more keywords
1140. GATA2 Mutations Are Frequently Identified Among Patients With Myeloid Malignancies Who Develop Invasive Aspergillosis
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.973
Abstract: Abstract Background Patients with myeloid malignancies are at risk of invasive aspergillosis (IA), a cause of significant morbidity and mortality. Identification of patients at higher risk for IA may help optimize prophylactic or preemptive treatment… read more here.
Keywords: gata2 mutations; risk; among patients; invasive aspergillosis ... See more keywords
Wilms' tumor and preferentially expressed antigen of melanoma in patients with myeloid neoplasms treated with azacytidine
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Haematology"
DOI: 10.1111/ejh.13312
Abstract: In their recent paper, Santaliestra et al measured bone marrow (BM) Wilms' tumor (WT1) mRNA levels in patients with myeloid neoplasms treated with 5-azacytidine (5-AZA)1 . Patients with initial WT1 levels greater than 100 copies but… read more here.
Keywords: myeloid neoplasms; tumor preferentially; neoplasms treated; treated azacytidine ... See more keywords
Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.614488
Abstract: Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with malignant hematologic diseases. Killer immunoglobin-like receptor (KIR) expressed by NK cells is closely associated with the transplant outcomes, and it has been widely… read more here.
Keywords: disease; hla; decreased ikir; patients myeloid ... See more keywords
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.923809
Abstract: Introduction Cytogenetic analysis is important for stratifying patients with various neoplasms. We explored the use of targeted next generation sequencing (NGS) in detecting chromosomal structural abnormalities or copy number variations (CNVs) in patients with myeloid… read more here.
Keywords: cell free; targeted ngs; myeloid neoplasms; free dna ... See more keywords